Vol 72, No 1 (2022)
Review paper
Published online: 2022-02-09

open access

Page views 5231
Article views/downloads 264
Get Citation

Connect on Social Media

Connect on Social Media

Hepatocellular cancer and colorectal liver metastasis treatment in the older population

Jakub Kenig1
Nowotwory. Journal of Oncology 2022;72(1):52-57.


More than 60% of patients with primary and secondary liver tumors are older than 65 years. Thanks to improvements in radiological staging, anesthesia, surgical technique, and perioperative care it is possible to offer complex liver surgery to older patients. However, chronological age or functional status alone should not be a contraindication for multimodal radical treatment in older patients. Fit patients, according to the Comprehensive Geriatric Assessment, should be qualified for the same treatment as younger patients to ensure the same outcomes. Prefrail patients should undergo prehabilita­tion, and be reevaluated. Frail patients should be discussed in an oncogeriatric meeting. All patients with liver malignant tumors must be operated on in high-volume hospitals by an experienced surgeon. The introduction of parenchymal sparing surgery (instead of a major resection) in combination with other treatment tools, minimal invasive techniques, and enhanced postoperative recovery demonstrated being beneficial for older patients. In particular, frail, older patients can benefit from the wide variety of treatment options.

Article available in PDF format

View PDF Download PDF file


  1. Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control. 2018; 25(1): 1073274817744621.
  2. Federico P, Giunta EF, Pappalardo A, et al. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel). 2021; 14(3).
  3. Marchesini G, Bua V, Brunori A, et al. Galactose elimination capacity and liver volume in aging man. Hepatology. 1988; 8(5): 1079–1083.
  4. Jansen PLM. Liver disease in the elderly. Best Pract Res Clin Gastroenterol. 2002; 16(1): 149–158.
  5. Frith J, Jones D, Newton JL. Chronic liver disease in an ageing population. Age Ageing. 2009; 38(1): 11–18.
  6. Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res. 2011; 2011: 831536.
  7. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989; 9(2): 297–301.
  8. Zoli M, Magalotti D, Bianchi G, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing. 1999; 28(1): 29–33.
  9. Schmucker DL, Gilbert R, Jones AL, et al. Effect of aging on the hepatobiliary transport of dimeric immunoglobulin A in the male Fischer rat. Gastroenterology. 1985; 88(2): 436–443.
  10. Brouwer A, Barelds RJ, Knook DL, et al. Maintenance cultures of Kupffer cells isolated from rats of various ages: ultrastructure, enzyme cytochemistry, and endocytosis. Hepatology. 1983; 3(4): 497–506.
  11. Farges O, Goutte N, Bendersky N, et al. ACHBT-French Hepatectomy Study Group. Incidence and risks of liver resection: an all-inclusive French nationwide study. Ann Surg. 2012; 256(5): 697–704; discussion 704.
  12. Tzeng CWD, Cooper AB, Vauthey JN, et al. Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients. HPB (Oxford). 2014; 16(5): 459–468.
  13. Kenig J. Oncogeriatrics (part 1.). Frailty in older adults with cancer. Nowotwory. Journal of Oncology. 2019; 69(2): 55–57.
  14. Loh KP, Soto-Perez-de-Celis E, Hsu T, et al. What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. J Oncol Pract. 2018; 14(2): 85–94.
  15. Grodzicki T, Kenig J. Problemy okołooperacyjne u osób w wieku podeszłym. PZWL Wydawnictwo Lekarskie, Warszawa 2018.
  16. Kenig J, Szabat K. Oncogeriatrics (part 7.). Geriatric assessment for older patients with cancer. Nowotwory. Journal of Oncology. 2020; 70(4): 153–157.
  17. Rostoft S, van Leeuwen B. Frailty assessment tools and geriatric assessment in older patients with hepatobiliary and pancreatic malignancies. Eur J Surg Oncol. 2021; 47(3 Pt A): 514–518.
  18. Forner A, Llovet J, Bruix J. Hepatocellular carcinoma. The Lancet. 2012; 379(9822): 1245–1255.
  19. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014; 63(5): 844–855.
  20. Oishi K, Itamoto T, Kohashi T, et al. Safety of hepatectomy for elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2014; 20(41): 15028–15036.
  21. Wu CC, Chen JT, Ho WL, et al. Liver resection for hepatocellular carcinoma in octogenarians. Surgery. 1999; 125(3): 332–338.
  22. Hazama H, Omagari K, Matsuo I, et al. Clinical features and treatment of hepatocellular carcinoma in eight patients older than eighty years of age. Hepatogastroenterology. 2001; 48(42): 1692–1696.
  23. Shirabe K, Kajiyama K, Harimoto N, et al. Early outcome following hepatic resection in patients older than 80 years of age. World J Surg. 2009; 33(9): 1927–1932.
  24. Nanashima A, Abo T, Nonaka T, et al. Prognosis of patients with hepatocellular carcinoma after hepatic resection: are elderly patients suitable for surgery? J Surg Oncol. 2011; 104(3): 284–291.
  25. Yamada S, Shimada M, Miyake H, et al. Outcome of hepatectomy in super-elderly patients with hepatocellular carcinoma. Hepatol Res. 2012; 42(5): 454–458.
  26. Tsujita E, Utsunomiya T, Yamashita Y, et al. Outcome of hepatectomy in hepatocellular carcinoma patients aged 80 years and older. Hepatogastroenterology. 2012; 59: 1553.
  27. Katsuta E, Tanaka S, Mogushi K, et al. Age-related clinicopathologic and molecular features of patients receiving curative hepatectomy for hepatocellular carcinoma. Am J Surg. 2014; 208(3): 450–456.
  28. Nozawa A, Kubo S, Takemura S, et al. Hepatic resection for hepatocellular carcinoma in super-elderly patients aged 80 years and older in the first decade of the 21st century. Surg Today. 2015; 45(7): 851–857.
  29. Notarnicola M, Felli E, Roselli S, et al. Laparoscopic liver resection in elderly patients: systematic review and meta-analysis. Surg Endosc. 2019; 33(9): 2763–2773.
  30. Sahara K, Paredes AZ, Tsilimigras DI, et al. Impact of Liver Cirrhosis on Perioperative Outcomes Among Elderly Patients Undergoing Hepatectomy: the Effect of Minimally Invasive Surgery. J Gastrointest Surg. 2019; 23(12): 2346–2353.
  31. Federico P, Giunta EF, Pappalardo A, et al. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel). 2021; 14(3).
  32. Dolnikov S, Adam R, Cherqui D, et al. Liver transplantation in elderly patients: what do we know at the beginning of 2020? Surg Today. 2020; 50(6): 533–539.
  33. Gómez Gavara C, Esposito F, Gurusamy K, et al. Liver transplantation in elderly patients: a systematic review and first meta-analysis. HPB (Oxford). 2019; 21(1): 14–25.
  34. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3): 1020–1022.
  35. Cucchetti A, Piscaglia F, Cescon M, et al. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol. 2013; 19(26): 4106–4118.
  36. Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010; 25(2): 403–407.
  37. Takahashi H, Mizuta T, Kawazoe S, et al. Efficacy and safety of radiofrequency ablation for elderly hepatocellular carcinoma patients. Hepatol Res. 2010; 40(10): 997–1005.
  38. Yamazaki H, Tsuji K, Nagai K, et al. Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma. Hepatol Res. 2014; 44(11): 1095–1101.
  39. Zhang F, Wu G, Sun H, et al. Radiofrequency ablation of hepatocellular carcinoma in elderly patients fitting the Milan criteria: a single centre with 13 years experience. Int J Hyperthermia. 2014; 30(7): 471–479.
  40. Yau T, Yao TJ, Chan P, et al. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. Cancer. 2009; 115(23): 5507–5515.
  41. Cohen MJ, Levy I, Barak O, et al. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J Gastroenterol. 2013; 19(16): 2521–2528.
  42. Cohen MJ, Levy I, Barak O, et al. Trans-arterial chemo-embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database. Liver Int. 2014; 34(7): 1109–1117.
  43. Nishikawa H, Kita R, Kimura T, et al. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients. J Cancer. 2014; 5(7): 590–597.
  44. Golfieri R, Bilbao JI, Carpanese L, et al. European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. J Hepatol. 2013; 59(4): 753–761.
  45. Guilherme NM, da Fonseca LG, Braghiroli MG, et al. Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma. Clinics. 2021; 76: 123–130.
  46. Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011; 16(12): 1721–1728.
  47. Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013; 30(1): 446.
  48. Jo M, Yasui K, Kirishima T, et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol Res. 2014; 44(13): 1329–1338.
  49. Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011; 41(4): 296–302.
  50. Edeline J, Crouzet L, Le Sourd S, et al. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemother Pharmacol. 2015; 75(1): 215–219.
  51. Kinoshita A, Koike K, Nishino H. Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatr Gerontol Int. 2017; 17(2): 189–201.
  52. Suda T, Nagashima A, Takahashi S, et al. Active treatments are a rational approach for hepatocellular carcinoma in elderly patients. World J Gastroenterol. 2013; 19(24): 3831–3840.
  53. Cho SW, Steel J, Tsung A, et al. Safety of liver resection in the elderly: how important is age? Ann Surg Oncol. 2011; 18(4): 1088–1095.
  54. de Liguori Carino N, van Leeuwen BL, Ghaneh P, et al. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol. 2008; 67(3): 273–278.
  55. Figueras J, Ramos E, López-Ben S, et al. Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clin Transl Oncol. 2007; 9(6): 392–400.
  56. Menon KV, Al-Mukhtar A, Aldouri A, et al. Outcomes after major hepatectomy in elderly patients. J Am Coll Surg. 2006; 203(5): 677–683.
  57. Adam R, Frilling A, Elias D, et al. LiverMetSurvey Centres. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010; 97(3): 366–376.
  58. Cannon RM, Martin RCG, Callender GG, et al. Safety and efficacy of hepatectomy for colorectal metastases in the elderly. J Surg Oncol. 2011; 104(7): 804–808.
  59. Orcutt ST, Artinyan A, Li LT, et al. Postoperative mortality and need for transitional care following liver resection for metastatic disease in elderly patients: a population-level analysis of 4026 patients. HPB (Oxford). 2012; 14(12): 863–870.
  60. Mann CD, Neal CP, Pattenden CJ, et al. Major resection of hepatic colorectal liver metastases in elderly patients - an aggressive approach is justified. Eur J Surg Oncol. 2008; 34(4): 428–432.
  61. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341(27): 2061–2067.
  62. Song W, Wang K, Zhang RJ, et al. The enhanced recovery after surgery (ERAS) program in liver surgery: a meta-analysis of randomized controlled trials. Springerplus. 2016; 5: 207.
  63. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8): 1386–1422.
  64. Rinaldi F, George E, Adler AI. NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy. Lancet Oncol. 2012; 13(3): 233–234.
  65. Tufo A, Dunne DFj, Manu N, et al. Changing outlook for colorectal liver metastasis resection in the elderly. Eur J Surg Oncol. 2019; 45(4): 635–643.
  66. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012; 4: 283–301.
  67. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27(22): 3677–3683.
  68. Taner T, Atwell TD, Zhang L, et al. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. HPB (Oxford). 2013; 15(3): 190–195.
  69. Mohan H, Nicholson P, Winter DC, et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol. 2015; 26(7): 935–942.e1.
  70. Baere Tde, Deschamps F, Tselikas L, et al. GEP-NETS UPDATE: Interventional radiology: role in the treatment of liver metastases from GEP-NETs. European Journal of Endocrinology. 2015; 172(4): R151–R166.
  71. Song W, Wang K, Zhang RJ, et al. The enhanced recovery after surgery (ERAS) program in liver surgery: a meta-analysis of randomized controlled trials. Springerplus. 2016; 5: 207.
  72. Kennedy AS, Ball DS, Cohen SJ, et al. Metastatic Colorectal Cancer Liver Metastases Outcomes After Radioembolization (MORE) Study Investigators. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer. Clin Colorectal Cancer. 2016; 15(2): 141–151.e6.

Nowotwory. Journal of Oncology